Key facts
- This page summarizes Dario A. Paggiarino's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 30 Jan 2024, 16:53.
Dario A. Paggiarino - 26 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- EYPT
- Reported as of
- 26 Jan 2024
- Net transaction value
- -$621,492
- SEC form
- 4
- Accepted by SEC
- 30 Jan 2024, 16:53:11 UTC
- Prior SEC filing
- 29 Jan 2024
- Next SEC filing
- 13 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron Honig, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dario A. Paggiarino filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 30 Jan 2024.
Change
- Previous filing in this sequence was filed on 29 Jan 2024.
- Current net transaction value: -$621,492.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EYPT
transaction
Common Stock
Options Exercise
- Transaction value
- $201,356
- Shares
- +15,609
- Change %
- +43%
- Price
- $12.90
- Shares after
- 52,114
- Date
- 26 Jan 2024
- Ownership
- Direct
EYPT
transaction
Common Stock
Options Exercise
- Transaction value
- $670
- Shares
- +51
- Change %
- +0.1%
- Price
- $13.13
- Shares after
- 52,165
- Date
- 26 Jan 2024
- Ownership
- Direct
EYPT
transaction
Common Stock
Options Exercise
- Transaction value
- $442,021
- Shares
- +33,665
- Change %
- +65%
- Price
- $13.13
- Shares after
- 85,830
- Date
- 26 Jan 2024
- Ownership
- Direct
EYPT
transaction
Common Stock
Sale
- Transaction value
- $1,296
- Shares
- -51
- Change %
- -0.06%
- Price
- $25.41
- Shares after
- 85,779
- Date
- 26 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
EYPT
transaction
Common Stock
Sale
- Transaction value
- $396,572
- Shares
- -15,609
- Change %
- -18%
- Price
- $25.41
- Shares after
- 70,170
- Date
- 26 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
EYPT
transaction
Common Stock
Sale
- Transaction value
- $867,672
- Shares
- -33,665
- Change %
- -48%
- Price
- $25.77
- Shares after
- 36,505
- Date
- 26 Jan 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -51
- Change %
- -0.1%
- Price
- $0.000000
- Shares after
- 51,253
- Date
- 26 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51
- Exercise price
- $13.13
- Footnotes
- F3
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -33,665
- Change %
- -66%
- Price
- $0.000000
- Shares after
- 17,588
- Date
- 26 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 33,665
- Exercise price
- $13.13
- Footnotes
- F3
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -15,609
- Change %
- -94%
- Price
- $0.000000
- Shares after
- 1,026
- Date
- 26 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,609
- Exercise price
- $12.90
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.62. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F3
The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
Footnote F4
The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020